Opendata, web and dolomites

HOXA9 degradome SIGNED

Deciphering the machinery involved in stability of the transcription factor HOXA9.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HOXA9 degradome project word cloud

Explore the words cloud of the HOXA9 degradome project. It provides you a very rough idea of what is the project "HOXA9 degradome" about.

poor    leukemia    clinical    integrating    druggable    acquire    global    crispr    plan    outcome    harvard    mutated    hits    shows    regulators    aberrantly    protein    molecular    elucidate    suitable    expression    screening    regulates    library    patients    dkfz    levels    platform    therapeutic    progression    network    pharmacologic    degradation    acute    nodes    stability    flexible    medical    dissection    combat    school    aggressive    hoxa9    career    perturbation    employing    strategy    controls    50    cas9    carcinogenesis    critical    machinery    tool    proteomics    cancer    abundance    undoubtedly    skills    transcription    summary    degradome    limitation    specificity    usa    performing    milestone    proteins    expressed    drive    candidate    elevated    malignancy    regulatory    aml    initiation    assessing    heidelberg    direct    intensify    alternative    master    interference    positive    validate    pharmaceutical    strategies    myeloid    screen    followed    hematopoiesis    inhibition    amenable    data    scientific    overcome    attractive    genes    facs   

Project "HOXA9 degradome" data sheet

The following table provides information about the project.

Coordinator
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG 

Organization address
address: IM NEUENHEIMER FELD 280
city: HEIDELBERG
postcode: 69120
website: www.dkfz.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://ebertlab.dana-farber.org/
 Total cost 239˙860 €
 EC max contribution 239˙860 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-GF
 Starting year 2016
 Duration (year-month-day) from 2016-11-07   to  2019-11-06

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG DE (HEIDELBERG) coordinator 239˙860.00
2    THE BRIGHAM AND WOMEN'S HOSPITAL INC US (BOSTON MA) partner 0.00

Map

 Project objective

Transcription factors are often mutated or aberrantly expressed in cancer and drive carcinogenesis. HOXA9 is a master transcription factor that controls a network of genes critical for hematopoiesis. It shows increased expression levels in more than 50% of patients with acute myeloid leukemia (AML), and is strongly associated with poor clinical outcome. Since the initiation and progression of AML depend on elevated HOXA9 levels, it represents an attractive therapeutic target to combat this aggressive malignancy. However, transcription factors are often not amenable to direct pharmacologic inhibition. To overcome this limitation, an alternative strategy aiming at interference with the transcription factor-specific 'degradome' - the degradation machinery regulates HOXA9 stability. To this end, we aim to elucidate the HOXA9 degradome with the goal of identifying its druggable nodes. Specifically, we plan to (1) identify regulatory proteins involved in the degradation of HOXA9 by performing a FACS-based positive selection screen with a focused CRISPR/Cas9 library as perturbation tool, (2) validate candidate proteins involved in the control of HOXA9 stability, and (3) characterize hits suitable for pharmacologic targeting. For the most promising HOXA9 regulators, we will determine their specificity by assessing global changes of protein abundance by proteomics. The potential of employing hits for pharmaceutical targeting will be evaluated by integrating molecular information with clinical data. In summary, this project aims to establish novel strategies for the dissection of the transcription factor HOXA9 degradome by developing a flexible screening platform. Through this project, I will not only acquire new skills but also establish a scientific network, which is expected to intensify the collaboration between DKFZ and Harvard Medical School. Two years’ experience in USA followed by one year in Heidelberg will be undoubtedly a milestone in my career development.

 Publications

year authors and title journal last update
List of publications.
2018 Quinlan L. Sievers, Georg Petzold, Richard D. Bunker, Aline Renneville, Mikołaj Słabicki, Brian J. Liddicoat, Wassim Abdulrahman, Tarjei Mikkelsen, Benjamin L. Ebert, Nicolas H. Thomä
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
published pages: eaat0572, ISSN: 0036-8075, DOI: 10.1126/science.aat0572
Science 362/6414 2019-02-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOXA9 DEGRADOME" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOXA9 DEGRADOME" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ICL CHROM (2020)

DNA interstrand crosslink repair and chromatin remodelling

Read More  

GENI (2019)

Gender, emotions and national identities: a new perspective on the abortion debates in Italy (1971-1981).

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More